Cafiero T, Esposito F, Fraioli G, Gargiulo G, Frangiosa A, Cavallo L M, Mennella N, Cappabianca P
A. Cardarelli Hospital, Burn Center and Hyperbaric Center, Postoperative Intensive Care, Department of Anaesthesia, University "Federico II", Naples, Italy.
Eur J Anaesthesiol. 2008 Aug;25(8):670-4. doi: 10.1017/S0265021508004195. Epub 2008 Apr 10.
To evaluate the use of remifentanil-propofol administered as target-controlled infusion during awake fibreoptic intubation for anticipated difficult tracheal intubation in acromegalic patients.
In all, 20 consecutive acromegalic patients underwent elective endonasal endoscopic transsphenoidal pituitary surgery. After premedication with midazolam 0.03 mg kg(-1), initially a target-controlled infusion of remifentanil 1.0 ng mL(-1) and propofol 1.5 microg mL(-1) was started. The fibreoptic intubation was performed by the same physician experienced with the fibreoptic technique. During the fibreoptic procedure the target concentrations of remifentanil and propofol ranged between 1.0 and 5.0 ng mL(-1), and between 1.5 and 3.5 microg mL(-1), respectively. Changes in heart rate and mean arterial pressure were recorded during airway manipulation, during tracheal intubation, and at 1 and 3 min after. On the first postoperative day, patient recall and level of discomfort during fibreoptic intubation were evaluated.
Endotracheal intubation was efficaciously and quickly secured in all patients. A significant increase in mean arterial pressure and heart rate was recorded only during tracheal intubation (P < 0.05). Oxygenation was sufficient and no bradypnea or apnoea was recorded. All patients later described their anaesthetic experience as satisfactory. During fibreoptic intubation, remifentanil (ng mL(-1)) and propofol (microg mL(-1)) mean effect-site concentrations were 3.2 +/- 0.3 and 2.0 +/- 1.0, respectively.
Remifentanil and propofol target-controlled infusion provided satisfactory conscious sedation allowing for successful oral fibreoptic intubation in acromegalic patients with no recall.
评估在肢端肥大症患者预计气管插管困难时,瑞芬太尼 - 丙泊酚靶控输注用于清醒纤维支气管镜插管的效果。
连续20例肢端肥大症患者接受择期鼻内镜经蝶垂体手术。在给予咪达唑仑0.03 mg·kg⁻¹进行术前用药后,最初启动瑞芬太尼1.0 ng·mL⁻¹和丙泊酚1.5 μg·mL⁻¹的靶控输注。纤维支气管镜插管由同一位有纤维支气管镜技术经验的医生进行。在纤维支气管镜操作过程中,瑞芬太尼和丙泊酚的靶浓度分别在1.0至5.0 ng·mL⁻¹和1.5至3.5 μg·mL⁻¹之间。记录气道操作期间、气管插管期间以及之后1分钟和3分钟时的心率和平均动脉压变化。在术后第一天,评估患者对纤维支气管镜插管期间的回忆及不适程度。
所有患者均有效且快速地完成了气管插管。仅在气管插管期间记录到平均动脉压和心率显著升高(P < 0.05)。氧合充足,未记录到呼吸过缓或呼吸暂停。所有患者后来都表示他们的麻醉体验令人满意。在纤维支气管镜插管期间,瑞芬太尼(ng·mL⁻¹)和丙泊酚(μg·mL⁻¹)的平均效应室浓度分别为3.2 ± 0.3和2.0 ± 1.0。
瑞芬太尼和丙泊酚靶控输注提供了令人满意的清醒镇静,使肢端肥大症患者成功进行了经口纤维支气管镜插管且无术中知晓。